Fresenius Medical Care AG (FMS)
Healthcare · NYQ
Price as at 1 Oct 2026, 01:56 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Fresenius Medical Care AG trades at $22.38, which is 25% below the $27.99 our fair value estimate puts on the business. On that measure alone it screens as undervalued, though a valuation model is an argument rather than a measurement, and the market is frequently right about why something is cheap.
Our moat model scores it 33 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
It changes hands at 12.9 times earnings. Be careful reading that in isolation: for a cyclical business a low P/E arrives at the top of the cycle, when profits are peaking and about to fall, which is exactly when the shares look cheapest and are not.
FMS dividend history
Dividends per share by year
| Year | Total per share | Payments |
|---|---|---|
| 2026 (year to date) | $0.872 | 1 |
| 2025 | $0.815 | 1 |
| 2024 | $0.634 | 1 |
| 2023 | $0.618 | 1 |
| 2022 | $0.709 | 1 |
| 2021 | $0.834 | 1 |
| 2020 | $0.707 | 1 |
| 2019 | $0.655 | 1 |
| 2018 | $0.632 | 1 |
| 2017 | $0.514 | 1 |
| 2016 | $0.440 | 1 |
Split-adjusted amounts in the listing currency, grouped by the calendar year of the ex-dividend date, from the filed record. Growth and streak figures compare complete years only.
FMS earnings and analyst estimates
Recommendation mix, 7 published ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About Fresenius Medical Care AG
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company operates through Care Delivery and Care Enablement segments. It also develops, manufactures, and distributes various health care products, including hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular specialty, ambulatory surgery center, physician nephrology practice management, pharmacy and other services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics, as well as through local sales forces, independent distributors, dealers, and sales agents. The company was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
FMS passes 4 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
9 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Richard Pzena, PZENA INVESTMENT MANAGEMENT LLC$338.97M · 1.0% of book
- Dodge & Cox, DODGE & COX$86.53M · 0.1% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$35.54M · 0.0% of book
- D. E. Shaw, D. E. Shaw & Co., Inc.$4.76M · 0.0% of book
- Cliff Asness, AQR CAPITAL MANAGEMENT LLC$1.92M · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Politician trades in FMS
We hold 8 disclosed trades in FMS by members of Congress and executive-branch officials. The latest 5:
- Alan Armstrong · SenateBuy · $1,001 - $15,000 · traded 30 Mar 2026 · disclosed 21 Jul 2026
- Daniel Goldman · HouseSell · $1,001 - $15,000 · traded 10 Jul 2023 · disclosed 13 Aug 2023
- Dean Phillips · HouseBuy · $1,001 - $15,000 · traded 12 Jan 2021 · disclosed 13 Feb 2021
- Dean Phillips · HouseBuy · $1,001 - $15,000 · traded 11 Jan 2021 · disclosed 13 Feb 2021
- Greg Gianforte · HouseSell · $100,001 - $250,000 · traded 2 Jan 2019 · disclosed 8 Feb 2019
A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.
FMS peers
The largest companies in the same industry (Medical Care Facilities), then in the same sector.
- FSNUY Fresenius SE & Co. KGaA
- THC Tenet Healthcare Corporation
- ENSG The Ensign Group, Inc.
- UHS Universal Health Services, Inc.
- RHC.AX Ramsay Health Care Limited
- CHE Chemed Corporation
- CON Concentra Group Holdings Parent, Inc.
- OPCH Option Care Health, Inc.
Every healthcare company we cover is on the Healthcare hub.
Common questions
Is Fresenius Medical Care AG (FMS) undervalued?
Against our fair value estimate of $27.99, FMS at $22.38 is 25% below fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.
Which funds own FMS?
9 of the institutions we track reported a position in FMS in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
What is FMS's P/E ratio?
FMS trades at 12.9 times earnings. A low P/E is not automatically cheap: on a cyclical company it is usually a warning that earnings are at a peak.
Does Fresenius Medical Care AG (FMS) pay a dividend?
Yes. Fresenius Medical Care AG yields 3.62% at the current share price. It has paid $0.872 per share over the trailing twelve months. It has paid a dividend in each of the last 28 complete calendar years. A dividend is declared by the board and can be cut at any time; a yield is a fact about the current price, not a promise.
Where does SteadyShares get its FMS data?
Fundamentals for FMS come from company filings and exchange data, as listed on NYQ; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 01:56 UTC and is delayed. Our data quality score for this company is 100/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for FMS, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.